Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the sixth annual BOTOX® Cosmetic Day will be Wednesday, ...
Morningstar28d
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
IRVINE, Calif., Oct. 18, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the ...
Stockhouse29d
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
IRVINE, Calif., Oct. 18, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the ...
Medscape26d
Nemolizumab Reassures in Long-Term Follow-Up Atopic Dermatitis Study
AMSTERDAM — The monoclonal antibody nemolizumab offers long-term efficacy and safety, as well as quality-of-life benefits, in the management of adolescents and adults with moderate to severe ...
PipelineReview.com27d
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
IRVINE, CA, USA I October 18, 2024 I Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX ® Cosmetic for temporary improvement in the appearance of ...
pharmaphorum3d
BlueRock clears key hurdle in Parkinson's stem cell trial
The results were described as "extremely encouraging" by Claire Henchcliffe of the University of California, Irvine ... of their candidate last year. AbbVie has finally claimed FDA approval ...
pharmaphorum8d
Regenxbio expands MPS I gene therapy trial after first look at data
While very early, the results are encouraging, according to Ray Wang, a specialist in metabolic disorders at the University of California, Irvine ... licensing deal with AbbVie for an AAV8 ...
Seeking Alpha4d
AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver
Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of ...
Seeking Alpha4d
How AbbVie can still benefit from Cerevel acquisition despite emraclidine setback
AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on schizophrenia asset emraclidine missed the primary endpoint. AbbVie ...